The Limited Times

Now you can see non-English news...

With results up in 2021, Sanofi expects strong growth in 2022

2022-02-04T07:01:23.050Z


The group announced this Friday an increase in its results in 2021, notably driven by the success of the Dupixent treatment.


Sanofi on Friday published sharply higher results in 2021, still boosted by its flagship treatment Dupixent, which continues to serve as a locomotive, allowing it to again increase the amount of dividends that will be paid to its shareholders.

Read alsoSanofi, GSK, Gilead, MSD…: these giants who missed the vaccination boat

In detail, net profit is down nearly 50%, to 6.22 billion euros.

Last year, it was boosted by the sale of a large part of Sanofi's shares in biotech Regeneron.

But net profit from activities, the indicator favored by the group, which excludes exceptional effects, rose by 11.8%, to 8.21 billion euros.

Source: lefigaro

All business articles on 2022-02-04

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.